AzTrials
AzTrials

UrolithiasisNCT02123082

Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes

A study testing Storz single Lumen Ureteroscope and Dual Lumen Ureteroscope in people with Urolithiasis, run by University of California, Irvine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Urolithiasis (kidney stones) is a common disease process affecting people all across the world. Usually, if the stone size is small, it is able to pass through the urinary system and exit the bladder on its own with no treatment. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Urolithiasis
What is being tested?
Storz single Lumen Ureteroscope and Dual Lumen Ureteroscope
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
156 participants
Where
1 siteUnited States
Study dates
2 Jul 2014to Apr 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patients >18 years old.
  • Patients with <2 cm total burden of renal or ureteral stones eligible for flexible ureteroscopic lithotripsy.

Who cannot join

  • Patients <18 years old.
  • Patients who are not able to give consent for study
  • Patients with active urinary tract infection
  • Pregnant women
  • Patients who have had ureteroscopy, SWL or PCNL for the same stone on the ipsilateral kidney

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of California, Irvine Medical Center

    Orange, California, 92868

Other trials in United States

About this study

Urolithiasis (kidney stones) is a common disease process affecting people all across the world. Usually, if the stone size is small, it is able to pass through the urinary system and exit the bladder on its own with no treatment. However, when the size of the stone is bigger, it can get trapped in the kidney or the ureter, causing significant pain for the patient and potentially obstructing urine flow. If this occurs, surgical treatment is necessary for the removal of the stone. The surgical procedure often employed involves the use of a ureteroscope, which is a device that includes a camera and channels for working instruments such as a grasper and laser fiber to be placed during a procedure. Ureteroscopes that are currently in use are flexible and have the ability to treat stones that may otherwise be inaccessible in the kidney. Most flexible ureteroscopes in clinical use currently only have one channel therefore only allowing one instrument to be used at a time. Recently, a new type of ureteroscope has been introduced in the market that offers the advantage of having two working channels where two instruments can be inserted for use during stone treating procedure. This can potentially decrease procedure time for patients affected by kidney stones.

The purpose of this research is to compare the efficacy and safety of the ureteroscopes that have only one channel for instrument insertion with the newer ureteroscope that has two channels for utilization during stone treatment.

Read the detailed description

Study design

This study will be prospective, multi-institutional randomized controlled trial comparing single lumen and dual lumen ureteroscopes. Specifically, a new double-lumen ureteroscope will be compared in a multicenter trial with the currently existing single-lumen ureteroscopes in patients undergoing ureteroscopy for stones in the kidney and ureter.

Patient Recruitment and Randomization

All patients presenting to the Department of Urology at University of California, Irvine, University of Toronto and North Shore-LIJ Health System requiring a flexible ureteroscopy for treatment of their kidney or ureteral stone disease will be approached for enrolment in the study, assuming the inclusion and exclusion criteria detailed below are met. After discussion of the study with potential participants, interested parties will be given a copy of the consent form. The investigator will review and explain the consent form with the potential subject. All information about the study will be provided. Ample time will be given for individuals to ask questions regarding participation and to have questions answered prior to signing the consent form. If so desired, those interested will be given a copy of the consent form to take home so that they may have the opportunity to discuss participation further with family and/or advisors. If an individual chooses to enroll, the consent form will be signed before procedure begins. Once an individual joins the study and informed consent is obtained, the subject will receive a signed copy of the consent form. Individuals may chose not be enrolled in the study or may withdraw from the study at any time without repercussions to subsequent care.

Patients agreeing to participate in the study will be randomized on the day of surgery. Stratified block randomization will be utilized to balance the number of patients with different stone sizes (>1cm, <1cm), kidney, proximal and distal ureteral stones between the two groups.

Device description

The Wolf Cobra Richard (Wolf Endoscopy, Vernon Hills, IL), a dual-lumen flexible ureteroscope is currently the only existing device with two working channels utilized in the operating room. Wolf Cobra has a shaft size of 9.9F. Each of the Cobra's two channels is 3.3 F in size (smaller compared with regular ureteroscopes 3.6F) but give a larger total cross-sectional area when two combined together. Atraumatic 6 Fr. distal tip dilates to a 9.9 Fr. sheath for ease of entry.

A dual-channel ureteroscope may provide several advantages. Having additional working channel enables better irrigation than a single-channel ureteroscope. It is achieved by continuous inflow and outflow, which might significantly, improve intraoperative visualization and maintains a clear field of view by efficient cleaning of blood, debris, and stone, even when utilizing multiple instruments simultaneously. Usually, multiple passes with different instruments requires the surgeon to reposition the ureteroscope in order to change the instruments which can potentially reduce efficiency and increase the length of operative time. The second working channel will allow the surgeon to use multiple instruments simultaneously while maintaining the flow and efficiently treat the stone or other pathology (Figure 1). This feature may offer technical advantages

Outcomes

Preoperatively, all patients will undergo a diagnostic imaging (CT, KUB, US) to identify the stone burden and location. Follow up imaging will be standardized across all participating institutions and will include CT or KUB imaging after the procedure to identify residual stones.

The primary outcome of the study will be the procedure time (minutes). This will be measured from the start of the endoscopic access to the end of the procedure including complete fragmentation and stone fragment removal.

The following data will also be recorded and serve as the secondary outcomes:

  1. Stone clearance rate (Will be defined by URS and postoperative imaging)
  2. Total ureteroscopy time
  3. Stone fragmentation time (this time will be recorded from start of first lithotripsy till complete stone fragmentation)
  4. Stone clearance time
  5. Overall procedure time (including positioning, URS procedure, extubation)
  6. Requirement for a second procedure
  7. Intraoperative complications
  8. Immediate postoperative complications
  9. Postoperative complications within 30 days of the procedure
  10. Surgeon's opinion and comfort (rank from 1-10?)
  11. Visibility using a questionnaire or rank from 1 to 10.
  12. Ureteroscope durability

Additionally, patient demographics and clinical characteristics such as age, gender, Charlson comorbidity index, ASA, BMI, previous medical and surgical history will be collected. Stone characteristics such as size, location, density (HU) will be recorded. For each patient, three (width, length and depth) largest diameters of the stone will be measured from preoperative CT and volume will be calculated for accurate stone measurements. All preoperative and postoperative outcomes will be compared based on the stone characteristics such as size, location and type of stone (HU)

Deflection Angles

New single lumen and double lumen ureteroscopes will be used for the purpose of this study. To avoid any confounding factors, these scopes will be used exclusively on patients who are involved in the trial. Every week each ureteroscope will be assessed for maximal deflection, which is defined as the angle between the tangents of the deflection point and the tip of the ureteroscopes, as described by Monga and Parkin9,10. In order to calculate the angle, a photocopy of the ureteroscope while in maximal deflection will be taken. Both upward and downward angles of deflections will be measured three times and the mean value will be subsequently calculated for each type of ureteroscope prior to first usage. These measurements will be performed after each week of usage. After the last case of the study, the maximal angle of deflection for each of the two types of ureteroscopes will be measured again and will be compared to the measurement at the beginning of the study.

Fatigability Fatigability of a given ureteroscope is defined as decrease of the maximum amount of deflection of the tip4. The fatigability of each ureteroscope will be measured by subtracting the mean value of maximal deflection at the end of the study from the maximum deflection measured at the beginning of the study.

Subjective Assessments

After each procedure, the surgeon that performs the endoscopic procedure will be asked to rate the image quality of the scope by filling out a questionnaire from 1-10 (1 being poor and 10 being excellent visualization). These subjective assessments will be the investigators secondary outcomes. Additionally, the ease of deflection and overall scope performance will be asked.

Once each ureteroscope reaches a point where it will require repair, it will be shipped to the manufacturing company. The reason for repair will be recorded, and the type and cost of each repair will be documented.

Conditions
Urolithiasis
Being tested
Storz single Lumen Ureteroscope, Dual Lumen Ureteroscope
Keywords
Urolithiasis, Kidney stones, Ureteral Obstruction, Ureteroscopes, Ureteroscopies
Medical subject headings
Urolithiasis, Kidney Calculi, Ureteral Obstruction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Storz single Lumen UreteroscopeDevice

    Also called Storz

    Single lumen, flexible scope for ureteroscopies

  • Dual Lumen UreteroscopeDevice

    Also called Wolf Cobra

    Dual lumen, flexible scope for ureteroscopies

Study groups in NCT02123082
Study groupRoleWhat they receive
Single-Lumen UreteroscopeOtherSubjects enrolled in this study arm will have their procedure performed using the single lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
Receives: Device: Storz single Lumen Ureteroscope; Device: Dual Lumen Ureteroscope
Dual Lumen UreteroscopeExperimentalSubjects enrolled in this study arm will have their procedure performed using the dual lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
Receives: Device: Storz single Lumen Ureteroscope; Device: Dual Lumen Ureteroscope

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time

    The primary outcome of the proposed study will be the procedure time in minutes measured from the start of the endoscopic access to the end of the procedure including complete fragmentation and stone fragment removal.

    Measured: Day 1 (Day of procedure)

Secondary outcomes (3)
  1. Complications

    The secondary outcomes are going to be requirement for a second procedure, intraoperative complications, immediate postoperative complications, postoperative complications within 30 days of the procedure.

    Measured: Days 1-30

  2. Time

    Total Ureteroscopy time, stone fragmentation time, stone clearance time and overall procedure time.

    Measured: Days 1-30

  3. Device efficacy

    Surgeon's opinion and comfort (scale 1-10), visibility (1-10), and ureteroscope durability.

    Measured: Procedure day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Apr 2014 (estimated)
  2. Study start2 Jul 2014
  3. Primary completionApr 2021
  4. Study completionApr 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
156 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02123082
Sponsor's protocol ID
20141060
Status last verified
Mar 2025
First submitted
26 Mar 2014
Last updated
13 Mar 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Storz single Lumen Ureteroscope and Dual Lumen Ureteroscope in people with Urolithiasis, run by University of California, Irvine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time (time frame: Day 1 (Day of procedure)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in